Filing Flows › Insulet (PODD) › Q1 2025
Insulet (PODD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Insulet (PODD) reported revenue of $569M for the first quarter 2025 (Q1 2025), +29% from a year earlier and -5% from the quarter before. Operating margin was 15.6%, net earnings $35.4M (6.2% of revenue).
Insulet, Q1 2025: revenue $569M (+29% year over year), operating margin 15.6%, net earnings $35.4M, operating cash flow $63.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $569M | -5% | +29% |
| Gross profit | $409M | -5% | +33% |
| Operating profit | $88.8M | -19% | +56% |
| Net earnings | $35.4M | -65% | -31% |
| Operating cash flow | $63.8M | -57% | -27% |
| Free cash flow | $51.5M | — | -21% |
What changed
Revenue was $569.0M in Q1 2025, up 29% year over year and down 5% from the previous quarter. U.S. was the largest line at 71% of revenue. U.S. added $84.0M year over year (up 26%), 66% of the total change.
Gross margin was 71.9%, up 2.4 points from a year earlier. Operating profit was $88.8M, a 15.6% margin (up 2.7 points year over year). Of the extra revenue versus a year earlier, 25% reached operating profit, above the 13% margin then. Operating expenses grew 28% against revenue growth of 29%. The fastest-growing cost line was SG&A (+31%). Net earnings were $35.4M, down 31% year over year. The effective tax rate was 26.3%.
Operating cash flow was $63.8M (down 27% year over year), 180% of net earnings. Non-cash charges added back $21.7M of depreciation and amortization and $18.2M of share-based compensation. Working capital and other items used $11.5M. After capital expenditures ($12.3M), free cash flow as the company reports it was $51.5M.
Questions
What was Insulet's revenue in the first quarter 2025?
Insulet (PODD) reported revenue of $569M for the first quarter 2025 (Q1 2025), +29% from a year earlier and -5% from the quarter before.
Was Insulet profitable in the first quarter 2025?
Operating profit was $88.8M (15.6% of revenue) and net earnings $35.4M.
Source: Insulet 10-Q on SEC EDGAR.